• Home
  • News
  • University of Manchester technology that boosts the understanding of senescent cells role in age-related disorders licensed to Arriani Pharmaceuticals

University of Manchester technology that boosts the understanding of senescent cells role in age-related disorders licensed to Arriani Pharmaceuticals

An exclusive licence deal has been transacted by The University of Manchester’s technology transfer company (UMI3 Ltd) with Arriani Pharmaceuticals for a research tool which boosts the understanding of senescent cells role in diverse age-related diseases including cancer.

Professors Vassilis Gorgoulis and Paul Townsend are behind the universally applicable method, called SenTraGorΤΜ, which enables better detection of senescence (the aging of cells).

Professor Townsend described the licence as “ground-breaking” and said: “Cellular senescence is causally linked to ageing and has been implicated in a variety of age-related diseases such as cancer.

“But up to now, detecting senescence was problematic and infeasible in most widespread biological material.

The agreement will see Arriani provide SenTraGorΤΜ to research institutions, diagnostic labs, clinics and companies looking for new therapies and offering wider well-being services to the public. Harry Lambridis, President and Founder of Arriani comments: “We are proud to offer to the international scientific community the valuable outcome of the research conducted by Professors Vassilis Gorgoulis and Paul Townsend that will revolutionalise the detection of senescent cells. We strongly believe that SenTraGorΤΜ will greatly contribute in the understanding of age-related biological processes and to this end we will work closely with the Professors to enlarge the applications of SenTraGorΤΜ, even beyond this field.”

The University of Manchester’s Professor Paul Townsend and Honorary Professor Vassilis Gorgoulis are world experts in cancer biology.

Professor Townsend said the agreement will bring considerable benefits to research and clinical practice and even beyond that around the world.

 

“Our method provides unheard-of advantages over any other available senescence detection products,” he said.

“It’s widely applicable, straight forward and specific. It will also help researchers make new breakthroughs into the causes of diseases, including cancer, as there will be a more effective understanding of phenomenon of cellular senescence. Moreover, its application can be expanded even to the cosmetics and food industries.”

Professor Gorgoulis added: “SenTraGorΤΜ revolutionizes the field of cellular aging and opens the door to a better understanding and treatment of various disorders. Many cancer types, degenerative diseases, even infertility, are thought to be senescence-related and our method introduces a powerful weapon in the medical armory against these conditions.”

Dr Rich Ferrie, Director of Operations at UMIP, commented: “We are delighted to have secured this licence deal with our new partners, Arriani. The strong commercial team at Arriani will ensure that this exciting product is quickly rolled out internationally and we are confident that the relationship we have established together will be both successful and enduring.”

CONTACT US
  • Home
  • News
  • University of Manchester technology that boosts the understanding of senescent cells role in age-related disorders licensed to Arriani Pharmaceuticals